Literature DB >> 26557981

Factors predicting use of laxatives in outpatients stabilized on clozapine.

Loren Bailey1, Seema Varma2, Nina Ahmad3, Siobhan Gee1, David M Taylor4.   

Abstract

Constipation is a common and sometimes fatal side effect of clozapine treatment. In this study, we aimed to identify factors associated with clozapine-induced constipation. Data on 202 outpatients stabilized on clozapine treatment were collected. Of these, 71 patients (35%) had a current prescription for laxatives (a proxy for the presence of constipation). Mean clozapine dose was 400.4 mg/day in those prescribed laxatives and 390.1 mg/day in those not prescribed laxatives (p = 0.67), while mean clozapine plasma concentration was 0.53 mg/l and 0.49 mg/l, respectively (p = 0.29). Patients using laxatives had on average 29% higher norclozapine concentrations (mean = 0.34 mg/l) than those who did not use laxatives (mean = 0.27 mg/l; p = 0.046). Laxative use was more common in female patients (49.1%) than male patients (29.1%; p < 0.01). Prescribers should be vigilant for constipation at any dose or plasma concentration of clozapine and should be mindful that male patients may be undertreated. Norclozapine concentrations may predict clozapine-induced constipation.

Entities:  

Keywords:  N-desmethylclozapine; clozapine; constipation; laxatives

Year:  2015        PMID: 26557981      PMCID: PMC4622118          DOI: 10.1177/2045125315591917

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  18 in total

1.  Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.

Authors:  Mong-Liang Lu; Hsien-Yuan Lane; Shih-Ku Lin; Kun-Po Chen; Wen-Ho Chang
Journal:  J Clin Psychiatry       Date:  2004-06       Impact factor: 4.384

2.  Clozapine-induced gastrointestinal hypomotility.

Authors:  Jane Vella-Brincat; Andrew McKean; Murray Barclay
Journal:  Australas Psychiatry       Date:  2011-10       Impact factor: 1.369

Review 3.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 4.  Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment.

Authors:  Erin J Lowe; Margaret L Ackman
Journal:  Ann Pharmacother       Date:  2010-03-16       Impact factor: 3.154

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

6.  Biotransformation of clozapine in humans.

Authors:  J G Dain; J Nicoletti; F Ballard
Journal:  Drug Metab Dispos       Date:  1997-05       Impact factor: 3.922

7.  Agonist activity of N-desmethylclozapine at delta-opioid receptors of human frontal cortex.

Authors:  Maria C Olianas; Simona Dedoni; Rossano Ambu; Pierluigi Onali
Journal:  Eur J Pharmacol       Date:  2009-02-23       Impact factor: 4.432

Review 8.  Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases.

Authors:  Susanna E Palmer; Rachael M McLean; Peter M Ellis; Mira Harrison-Woolrych
Journal:  J Clin Psychiatry       Date:  2008-05       Impact factor: 4.384

9.  Serum antimuscarinic activity during clozapine treatment.

Authors:  Jose de Leon; Aruby Odom-White; Richard C Josiassen; Francisco J Diaz; Thomas B Cooper; George M Simpson
Journal:  J Clin Psychopharmacol       Date:  2003-08       Impact factor: 3.153

10.  Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.

Authors:  Amin Rostami-Hodjegan; Ajmal M Amin; Edgar P Spencer; Martin S Lennard; Geoffrey T Tucker; Robert J Flanagan
Journal:  J Clin Psychopharmacol       Date:  2004-02       Impact factor: 3.153

View more
  9 in total

Review 1.  A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.

Authors:  Madeleine S A Tan; Faraz Honarparvar; James R Falconer; Harendra S Parekh; Preeti Pandey; Dan J Siskind
Journal:  Psychopharmacology (Berl)       Date:  2021-01-07       Impact factor: 4.530

2.  Lubiprostone for the Treatment of Clozapine-Induced Constipation: A Case Series.

Authors:  Tyler J Torrico; Snehpreet Kaur; Manik Dayal; Pooja Eagala; David Weinstein
Journal:  Cureus       Date:  2022-06-01

3.  The Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study.

Authors:  Susanna Every-Palmer; Pete M Ellis; Mike Nowitz; James Stanley; Eve Grant; Mark Huthwaite; Helen Dunn
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

Review 4.  Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment.

Authors:  Yue Xu; Nousayhah Amdanee; Xiangrong Zhang
Journal:  CNS Drugs       Date:  2021-08-24       Impact factor: 5.749

Review 5.  Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis.

Authors:  Ayala Shirazi; Brendon Stubbs; Lucia Gomez; Susan Moore; Fiona Gaughran; Robert J Flanagan; James H MacCabe; John Lally
Journal:  Int J Mol Sci       Date:  2016-06-02       Impact factor: 5.923

6.  Spatiotemporal Mapping Techniques Show Clozapine Impairs Neurogenic and Myogenic Patterns of Activity in the Colon of the Rabbit in a Dose-Dependent Manner.

Authors:  Susanna Every-Palmer; Roger G Lentle; Gordon Reynolds; Corrin Hulls; Paul Chambers; Helen Dunn; Pete M Ellis
Journal:  Front Pharmacol       Date:  2017-04-24       Impact factor: 5.810

Review 7.  Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement.

Authors:  Nilamadhab Kar; Socorro Barreto; Rahul Chandavarkar
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-11-30       Impact factor: 2.582

Review 8.  Adverse Drug Reactions in Relation to Clozapine Plasma Levels: A Systematic Review.

Authors:  Maria Skokou; Eleni A Karavia; Zoi Drakou; Vassiliki Konstantinopoulou; Christina-Anna Kavakioti; Philippos Gourzis; Kyriakos E Kypreos; Ourania Andreopoulou
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-01

9.  Clozapine-treated Patients Have Marked Gastrointestinal Hypomotility, the Probable Basis of Life-threatening Gastrointestinal Complications: A Cross Sectional Study.

Authors:  Susanna Every-Palmer; Mike Nowitz; James Stanley; Eve Grant; Mark Huthwaite; Helen Dunn; Pete M Ellis
Journal:  EBioMedicine       Date:  2016-02-15       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.